Prospective, non-interventional descriptive study to assess the impact on patient well-being of oral fixed-duration (FTD) and continuous regimens for first-line and relapsed/refractory chronic lymphocytic leukemia
OBSERVATIONAL STUDY WITH MEDICATION
Clinical trial information
- Promoter: ABBVIE SPAIN SLU
- Execution start: 27/06/2023
- End of execution: 30/03/2025
- IP: JOSE M PUERTA PUERTA